Enwei Pharmaceutical Co Ltd
SZSE:301331
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Enwei Pharmaceutical Co Ltd
Income from Continuing Operations
Enwei Pharmaceutical Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Enwei Pharmaceutical Co Ltd
SZSE:301331
|
Income from Continuing Operations
¥37.5m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Income from Continuing Operations
¥5.6B
|
CAGR 3-Years
29%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Income from Continuing Operations
¥8.1B
|
CAGR 3-Years
28%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Income from Continuing Operations
¥5.2B
|
CAGR 3-Years
22%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
7%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Income from Continuing Operations
¥6.8B
|
CAGR 3-Years
23%
|
CAGR 5-Years
14%
|
CAGR 10-Years
33%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Income from Continuing Operations
¥3.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
244%
|
CAGR 10-Years
N/A
|
|
Enwei Pharmaceutical Co Ltd
Glance View
Enwei Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of proprietary Chinese and chemical medicines. The company is headquartered in Chengdu, Sichuan and currently employs 1,610 full-time employees. The company went IPO on 2022-09-21. The firm focuses on gynecological products, pediatric medicines, respiratory medicines and other fields. The firm's main products include Jieeryin lotion, Jieeryin ointment, Jieeryin effervescent tablets, Shanmai Jianpi oral liquid, Qingjing capsules and Danxiong Tongmai granules. Its products are mainly sold through direct sales and e-commerce. The firm principally conducts its businesses in the domestic market.
See Also
What is Enwei Pharmaceutical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
37.5m
CNY
Based on the financial report for Dec 31, 2024, Enwei Pharmaceutical Co Ltd's Income from Continuing Operations amounts to 37.5m CNY.
What is Enwei Pharmaceutical Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-16%
Over the last year, the Income from Continuing Operations growth was -57%. The average annual Income from Continuing Operations growth rates for Enwei Pharmaceutical Co Ltd have been -28% over the past three years , -16% over the past five years .
